Cyclerion Therapeutics, Inc. Quarterly Operating Income (Loss) in USD from Q1 2018 to Q4 2024

Taxonomy & unit
us-gaap: USD
Description
The net result for the period of deducting operating expenses from operating revenues.
Summary
Cyclerion Therapeutics, Inc. quarterly/annual Operating Income (Loss) history and growth rate from Q1 2018 to Q4 2024.
  • Cyclerion Therapeutics, Inc. Operating Income (Loss) for the quarter ending December 31, 2024 was $502K.
  • Cyclerion Therapeutics, Inc. Operating Income (Loss) for the twelve months ending December 31, 2024 was -$3.63M, a 72% increase year-over-year.
  • Cyclerion Therapeutics, Inc. annual Operating Income (Loss) for 2024 was -$3.63M, a 72% increase from 2023.
  • Cyclerion Therapeutics, Inc. annual Operating Income (Loss) for 2023 was -$13M, a 30.1% increase from 2022.
  • Cyclerion Therapeutics, Inc. annual Operating Income (Loss) for 2022 was -$18.5M, a 66.4% increase from 2021.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Quarterly (USD)
Operating Income (Loss), YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q4 2024 -$3.63M $502K +$2.3M Oct 1, 2024 Dec 31, 2024 10-K 2025-03-04
Q3 2024 -$5.93M -$1.13M +$4.89M +81.2% Jul 1, 2024 Sep 30, 2024 10-Q 2024-11-14
Q2 2024 -$10.8M -$1.38M +$481K +25.8% Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-07
Q1 2024 -$11.3M -$1.62M +$1.66M +50.6% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-07
Q4 2023 -$13M -$1.8M -$14.2M -114% Oct 1, 2023 Dec 31, 2023 10-K 2025-03-04
Q3 2023 $1.24M -$6.02M -$1.5M -33.1% Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-14
Q2 2023 $2.74M -$1.87M +$11.6M +86.1% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-07
Q1 2023 -$8.83M -$3.28M +$9.71M +74.8% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-07
Q4 2022 -$18.5M $12.4M +$26.7M Oct 1, 2022 Dec 31, 2022 10-K 2024-03-05
Q3 2022 -$45.3M -$4.52M +$6.77M +60% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-13
Q2 2022 -$52M -$13.4M +$2.74M +17% Apr 1, 2022 Jun 30, 2022 10-Q 2023-07-28
Q1 2022 -$54.8M -$13M +$411K +3.07% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-12
Q4 2021 -$55.2M -$14.3M +$4.89M +25.4% Oct 1, 2021 Dec 31, 2021 10-K 2023-03-22
Q3 2021 -$60.1M -$11.3M +$10.5M +48.2% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-03
Q2 2021 -$70.6M -$16.2M +$3.5M +17.8% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-09
Q1 2021 -$74.1M -$13.4M +$7.19M +34.9% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-04
Q4 2020 -$81.3M -$19.2M +$7.36M +27.7% Oct 1, 2020 Dec 31, 2020 10-K 2022-02-24
Q3 2020 -$88.6M -$21.8M +$6.24M +22.3% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-09
Q2 2020 -$94.9M -$19.7M +$13.4M +40.5% Apr 1, 2020 Jun 30, 2020 10-Q 2021-07-29
Q1 2020 -$108M -$20.6M +$16.8M +44.9% Jan 1, 2020 Mar 31, 2020 10-Q 2021-04-30
Q4 2019 -$125M -$26.6M +$4.32M +14% Oct 1, 2019 Dec 31, 2019 10-K 2021-02-25
Q3 2019 -$129M -$28M +$1.27M +4.34% Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-05
Q2 2019 -$131M -$33.1M -$3.27M -11% Apr 1, 2019 Jun 30, 2019 10-Q 2020-08-03
Q1 2019 -$127M -$37.4M -$12.1M -47.9% Jan 1, 2019 Mar 31, 2019 10-Q 2020-05-04
Q4 2018 -$115M -$30.9M Oct 1, 2018 Dec 31, 2018 10-K 2020-03-12
Q3 2018 -$29.3M Jul 1, 2018 Sep 30, 2018 10-Q 2019-11-12
Q2 2018 -$29.8M Apr 1, 2018 Jun 30, 2018 10-Q 2019-08-12
Q1 2018 -$25.3M Jan 1, 2018 Mar 31, 2018 10-Q 2019-05-13
* An asterisk sign (*) next to the value indicates that the value is likely invalid.